Get alerted on the PharmaSources E-Newsletter and Pharma Sources Insight E-Compilation!
Note: You can unsubscribe from the alerts at any time.
Advertising

Exelixis Announces U.S. FDA Accepts Investigational New Drug Application for XB002 in Patients with Advanced Solid Tumors

americanpharmaceuticalreviewApril 07, 2021

Tag: Exelixis , FDA , XB002 , ADC , Advanced Solid Tumors

PharmaSources Customer Service